Singapore markets closed

T2 Biosystems, Inc. (TTOO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0500-0.1900 (-5.86%)
At close: 04:00PM EDT
3.1100 +0.06 (+1.97%)
Pre-market: 08:07AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.2400
Open3.3100
Bid3.0300 x 200
Ask3.0800 x 100
Day's range3.0301 - 3.4500
52-week range2.6000 - 70.0000
Volume373,449
Avg. volume338,729
Market cap26.818M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease

    Advances plan to launch T2Lyme Panel for detection of early Lyme diseaseFiled Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has signed a non-binding letter of intent (“LOI”) to enter into a strat

  • GlobeNewswire

    T2 Biosystems Announces First Quarter 2024 Financial Results

    Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year periodLEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024. Recent Financial and Operational Highlights Achieved first quarter 2024 sep

  • GlobeNewswire

    T2 Biosystems Announces Commercial Expansion Through Middle East Distributor

    Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Qatar. Under the terms of the agreement, T2 Biosystems will sell T2Dx® Instruments,